Atay Oguzhan sold $315K of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 2,667 indirectly-held shares of BillionToOne, Inc. (BLLN) at $118.00 ($0.31M total) on 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 30, 2026, 10:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The transaction provides fresh data on insider sentiment, which may influence short-term trading decisions.

02

Market read

Insider sell by the CEO is a modest but noteworthy event for traders monitoring BLLN.

03

What to watch

No immediate financial impact; the CEO still holds a substantial stake.

Relevance 3/10Novelty 3/10Timing: post-market filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Chairman and CEO Atay Oguzhan sold 2,667 shares for $314,706 via a 10b5-1 plan, reducing his stake to 146,501 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size but involves the CEO, which traders may view as a negative signal.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. investors tracking insider activity.

Low

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on NASDAQ under ticker BLLN.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.